Channel
@merlintraderpub_com
On this record: Topic · Growth · Engagement · Reactions · Posts · Cite this entry
21subscribers
+12 since we began measuring on 31 August 2026
Risers and fallers across the register · movement among entries of Under 1,000.
| Telegram ID | -1004485010109 |
|---|---|
| Type | Channel |
| Username | @merlintraderpub_com |
| Created | Between 1 June 2026 and 22 August 2026 — estimated from Telegram’s id allocation, not measured. How this range is calculated. |
| First recorded | 31 August 2026 |
| Last confirmed live | 4 October 2026 |
| Measurements held | 5 |
| Confirmed unchanged | 1 time, most recently 4 October 2026 |
| On Telegram | t.me/merlintraderpub_com |
Other / unclassifiable — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-FP8, prompt version 1) read this channel’s own recent posts on 1 October 2026 and assigned it the closest of 31 fixed categories, at 77% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and why it has no browse page of its own yet.
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 4 Oct 2026, 08:18 | 21 | +7 |
| 18 Sept 2026, 22:00 | 14 | +4 |
| 10 Sept 2026, 07:38 | 10 | +1 |
| 31 Aug 2026, 03:46 | 9 | no change |
| 31 Aug 2026, 03:35 | 9 | first reading |
20 posts held, back to 22 August 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 1 page of Telegram’s post history, 20 posts per page.
Nothing published in the last 30 days. ERR and ER are rolling 30-day measures, so there is nothing to compute — we hold 20 posts for this entry, the most recent from 28 August 2026. An engagement rate over an empty window would be a number about nothing.
1 reaction across 1 post, in 1 kind.
| Reaction | Count | Share | Share, drawn |
|---|---|---|---|
| ❤ | 1 | 100.0% |
No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.
Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.
Coverage. Reactions were read on 1 of the 20 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 1 reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.
Measured over the 20 most recent posts we hold, published 22 August 2026 to 28 August 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.
Oscar Health ($OSCR): a record first half, a raised guidance that implies a loss-making second half First half 2026: $9,527.4 million of revenue, a 75.0% medical loss ratio and $1,092.7 million of earnings from operations, against a full year 2025 that lost $396.4 million. Then the arithmetic. On August 6 the company raised full year guidance to $500-700 million of operating earnings. Subtract the half already book…
In bladder cancer there is a situation that looks like a clerical error and is actually the whole problem: five drugs are approved for disease that stops responding to BCG, and every one of them requires carcinoma in situ. For patients whose disease is papillary only, there is nothing approved anywhere in the world. BCG is a tuberculosis vaccine in use since 1976, and the world has a structural shortage of it: one m…
Omeros ($OMER): The Biotech With No Perfect Peer The deep dive has been rebuilt from the primary sources: twenty sections, six charts, every figure re-read on the filing it comes from. Three corrections to the first version: InflaRx's market value was computed on a pre-offering share count, the reference price was an intraday print, and options outstanding were read in the wrong unit. Four facts that were missing …
There is one setting in oncology where a patient can be in remission, free of detectable disease, and have no approved treatment at all: acute myeloid leukemia in second remission, in patients who cannot receive a transplant. Onureg is approved in first remission. Vanflyta in first remission, FLT3-ITD only. In second remission there is nothing, and what a patient receives is decided by their doctor: observation, an …
$VRCA — Verrica Pharmaceuticals: COVE-2 fully enrolled, topline data guided to the first quarter of 2027 Before the open this morning Verrica announced that enrollment in COVE-2, the first pivotal Phase 3 trial of YCANTH in common warts, is complete. A per-protocol interim power analysis by an independent statistician confirmed that no additional subjects are recommended, and the study remains fully blinded. Topline…
$RKLB — the Iridium vote now has a date, and the collar is doing something interesting Amendment No. 1 to the Form S-4, filed August 24, fixes the item that had no date: Iridium holds a special meeting on September 24, 2026 at 8:30 a.m. Eastern Time, virtual only. Record date was the close of August 21, so the holders who will decide are already determined. The threshold is the affirmative vote of a majority of the…
$BKSY — a Form 25 was filed today, and it covers the warrants, not the stock The New York Stock Exchange filed a Form 25-NSE naming BlackSky. A headline that stops at "Form 25" points a reader toward the wrong conclusion, so here is what the document actually says. The security it describes is the "Redeemable Warrants, each whole Warrant exercisable for one-eighth (1/8th) of a share of Class A Common Stock at an ex…
$AVAV — a $51 million U.S. Army order, announced today AeroVironment received a delivery order from the United States Army for additional Switchblade 600 Block 2 loitering munitions. The order also covers Block 1 systems supporting a Foreign Military Sale to an ally the release does not name. It was placed under the Army's existing five-year, $990 million Lethal Unmanned Systems IDIQ from August 2024, and follows t…
$CRML new stock hub. Critical Metals Corp holds a rare-earth project in southern Greenland and a lithium project in Austria, and has never reported revenue. Audited to June 30, 2025: loss after tax of $51.87M, cash of $7.30M, an accumulated deficit of $200.56M and a going-concern warning written by the company itself. A capitalisation table then shows $80.92M of cash and a deficit of $320.93M at December 31, 2025, r…
Candel Therapeutics ($CADL) Stock Hub New hub. The 745-patient phase 3 in localized prostate cancer met its primary endpoint under a Special Protocol Assessment and is published in The Lancet Oncology, with a 39% improvement in prostate cancer-specific disease-free survival at a median 58 months. BLA guided to Q4 2026. That is a company window, not an FDA date, and the company states that a process validation campa…
$SYRE — Spyre Therapeutics, new stock hub. Figures verified on August 26, 2026. Three of six planned Phase 2 readouts delivered this year. SPY001 in April and SPY002 in June both hit the primary endpoint in ulcerative colitis, cutting the Robarts Histopathology Index by 9.2 and 10.7 points. On August 25 SPY072 also hit its primary endpoint in rheumatoid arthritis, and the company still declined to advance it as a mo…
$BCRX — Japan approves ORLADEYO for children Japan's Ministry of Health, Labor and Welfare approved the granule formulation of ORLADEYO (berotralstat) on August 25 for children with hereditary angioedema aged 2 to under 12. It is the second Japanese approval for the product and the first pediatric clearance outside the United States. The launch still waits on the National Health Insurance reimbursement pricing proc…
Showing the 12 most recent of 20 posts we hold for @merlintraderpub_com. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 4 October 2026 — this entry's latest reading, not the date you are reading this.
“Merlintraderpub” (@merlintraderpub_com), 21 subscribers as measured 4 October 2026. Telegram Register, tgregister.com/channel/merlintraderpub_com.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.